KESIMPTA (ofatumumab) Patient Assistance Program
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Kesimpta (ofatumumab) is FDA-approved for relapsing forms of multiple sclerosis (MS) — including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS — in adults. It is a fully human anti-CD20 monoclonal antibody given as a once-monthly subcutaneous injection.
- Without assistance, Kesimpta costs commonly run approximately $7,500–$8,500 per monthly injection, with annual costs commonly $90,000–$100,000+.
- Through AffordMyPrescriptions, qualifying patients can access Kesimpta for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- There is no biosimilar of Kesimpta in the U.S. as of 2026. Other anti-CD20 MS therapies include ocrelizumab (Ocrevus, IV every 6 months), ublituximab (Briumvi, IV with shorter infusions), and rituximab (off-label, multiple biosimilars at lower cost).
What Is Kesimpta Prescription Assistance Program?
The Kesimpta Prescription Assistance Program is a manufacturer-sponsored initiative that provides Kesimpta at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for relapsing MS patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, neurology coordination, baseline immunoglobulin/screening documentation, prior-authorization documentation, specialty pharmacy logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and annual re-certification.
Pharmacy Price Comparison
- Without assistance, Kesimpta costs roughly $7,500–$8,500 per monthly injection. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$8,200/dose | Save ~$8,130/dose |
| CVS Pharmacy | ~$8,500/dose | Save ~$8,430/dose |
| Walmart | ~$7,700/dose | Save ~$7,630/dose |
| Costco | ~$7,600/dose | Save ~$7,530/dose |
Specialty Pharmacy | ~$7,800/dose | Save ~$7,730/dose |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Kesimpta Prescription Program?
The Patient Assistance Program is free to apply for and provides Kesimpta at no medication cost if approved. Our $69.95/month service covers full advocacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Kesimpta:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $7,500–$8,500/dose per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Kesimpta assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Kesimpta Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Kesimpta :
Kesimpta (ofatumumab) is a fully human anti-CD20 monoclonal antibody used to treat relapsing forms of multiple sclerosis. Unlike other anti-CD20 MS therapies that require IV infusions, Kesimpta is self-administered at home as a once-monthly subcutaneous injection.
How Kesimpta Works:
B-lymphocytes drive multiple sclerosis (MS) pathogenesis through autoantibody production, antigen presentation, and pro-inflammatory cytokine secretion. Ofatumumab is a fully human monoclonal antibody that binds to the CD20 surface marker on these cells with high affinity. This binding triggers rapid and sustained B-cell depletion through complement-dependent and antibody-dependent cellular cytotoxicity. Ultimately, this targeted depletion dramatically reduces MS relapse rates, slows disability progression, and decreases MRI lesion activity while offering the convenience of home dosing.
Form and use:
Kesimpta is self-administered as a subcutaneous injection using a prefilled syringe or Sensoready pen, which most patients can do at home after receiving proper training. The standard loading schedule consists of a 20 mg dose administered at weeks 0, 1, and 2. Following this initial phase, the ongoing maintenance dose is 20 mg once monthly, starting at week 4. Before a patient can begin treatment with this medication, a mandatory hepatitis B screening must be performed.
Generic availability:
As of 2026, there is no biosimilar version of Kesimpta available in the United States. Other anti-CD20 therapies for MS include ocrelizumab and ublituximab, which are administered as intravenous infusions every 6 months, as well as rituximab biosimilars that are widely used off-label at a lower cost. Additional disease-modifying therapy classes available for MS management include S1P modulators, interferons, glatiramer, oral agents like generic dimethyl fumarate, and natalizumab.
Warnings:
Kesimpta carries warnings for local and systemic injection reactions, which are typically mild and decrease with subsequent doses. It increases the risk of infections, such as upper respiratory and urinary tract infections, and carries a rare risk of progressive multifocal leukoencephalopathy (PML). The medication can reactivate hepatitis B, making active or untreated chronic HBV a contraindication, and long-term use can reduce immunoglobulin levels. Furthermore, live vaccines must be avoided, and any required live vaccinations should be completed at least 4 weeks prior to starting therapy.
FAQ (Frequently Asked Questions)
How Much Does Kesimpta Cost Without Insurance?
Kesimpta costs approximately $7,500–$8,500 per monthly injection, with annual costs commonly $90,000–$100,000+. Through AffordMyPrescriptions, qualifying patients receive Kesimpta at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
How Is Kesimpta Different From Ocrevus?
Both are anti-CD20 monoclonal antibodies for relapsing MS with similar effectiveness. Kesimpta (ofatumumab) is a once-monthly SC self-injection at home. Ocrevus (ocrelizumab) is an IV infusion every 6 months at an infusion center. Kesimpta offers convenience and home administration; Ocrevus offers less-frequent dosing and is also approved for primary progressive MS. Some patients prefer one over the other based on lifestyle and preferences.
How Quickly Will Kesimpta Work?
B-cell depletion is rapid — within days of the first dose. MS clinical benefit (reduced relapses, slowed disability) develops over months. Most patients experience a significant decrease in MS attacks within the first year of consistent dosing. MRI lesion activity is typically substantially reduced within 6 months.
Why Do I Need Hepatitis B Screening Before Starting?
Anti-CD20 therapy can reactivate hepatitis B in patients with current or past HBV infection. HBV screening (HBsAg, anti-HBc) is required before starting. Patients with active HBV cannot receive Kesimpta; patients with prior HBV exposure may need antiviral prophylaxis and close monitoring.
Can I Get Kesimpta Through The PAP If I Have Medicare?
Yes. Medicare Part D beneficiaries can typically qualify, especially if you face specialty-tier copays. The manufacturer’s commercial copay savings program is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria.
Should I Consider Rituximab Biosimilar Instead?
Some neurologists use rituximab (with multiple biosimilars available at lower cost) off-label for MS. Rituximab is dosed approximately every 6 months by IV infusion. The clinical effectiveness is similar to ocrelizumab and Kesimpta in many studies. Insurance coverage for off-label rituximab in MS varies. Discuss with your neurologist whether biosimilar rituximab might be a cost-effective alternative.
What If My Application Is Denied?
If denied, we explore alternatives — switching to Ocrevus or Briumvi with their own PAPs, off-label rituximab biosimilar at much lower cost, generic fingolimod, generic dimethyl fumarate, or another MS DMT, the manufacturer’s copay program for commercially insured patients, or independent foundations such as the National MS Society, MS Association of America, PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Kesimpta, our team may be able to help you access assistance programs designed to make brand specialty MS anti-CD20 biologic therapy affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.